BIS icon

ProShares UltraShort NASDAQ Biotechnology

11 hedge funds and large institutions have $6.05M invested in ProShares UltraShort NASDAQ Biotechnology in 2018 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 6 increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
11
Holders Change
Holders Change %
0%
% of All Funds
0.25%
Holding in Top 10
1
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.02%
New
2
Increased
6
Reduced
2
Closed
2
Calls
$1.4M
Puts
Net Calls
+$1.4M
Net Calls Change
+$1.57M
Name Holding Trade Value Shares
Change
Shares
Change %
HVC
1
Healthcare Value Capital
New Jersey
$1.59M +$1.06M +12,500 +200%
WP
2
WealthSource Partners
California
$1.18M +$518K +6,125 +78%
Susquehanna International Group
3
Susquehanna International Group
Pennsylvania
$1.04M +$95.5K +1,129 +10%
TRCT
4
Tower Research Capital (TRC)
New York
$596K +$91.1K +1,078 +18%
VF
5
Virtu Financial
New York
$592K -$982K -11,603 -62%
Citadel Advisors
6
Citadel Advisors
Florida
$362K +$86.9K +1,028 +32%
Simplex Trading
7
Simplex Trading
Illinois
$328K +$328K +3,885 New
Jane Street
8
Jane Street
New York
$227K +$227K +2,685 New
UBS Group
9
UBS Group
Switzerland
$68K +$57.6K +679 +552%
Citigroup
10
Citigroup
New York
$33K -$10.7K -125 -25%
Toronto Dominion Bank
11
Toronto Dominion Bank
Ontario, Canada
$30K
CA
12
Calton & Associates
Florida
-$22K -313 Closed
Morgan Stanley
13
Morgan Stanley
New York
-$25K -284 Closed